Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen

Journal of Veterinary Internal Medicine

Volumn 19, Issue 1, 2005, Pages 56-63

  Gyorffy, Steve ^a   Rodriguez Lecompte, Juan Carlos ^a   Woods, J Paul ^b   Foley, Ronan ^a   Kruth, Stephen ^b   Liaw, Patricia C Y ^a   Gauldie, Jack ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

Dendritic cell based vaccine; Gene therapy, Tolerance; Tumor immunotherapy, Vaccine

Indexed keywords

CD18 ANTIGEN; DENDRITIC CELL VACCINE; FLT3 LIGAND; GLYCOPROTEIN GP 100; GLYCOPROTEIN P 15095; HLA ANTIGEN CLASS 2; LYMPHOCYTE SURFACE MARKER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR; TUMOR NECROSIS FACTOR;

ADENOVIRUS VECTOR; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; BONE MARROW CULTURE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOG; DOG DISEASE; ELECTRON MICROSCOPY; IMMUNE RESPONSE; MELANOMA; MONONUCLEAR CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD18; BONE MARROW CELLS; CANCER VACCINES; DENDRITIC CELLS; DOG DISEASES; DOGS; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; GROWTH SUBSTANCES; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MOUTH NEOPLASMS; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS;

EID: 13544269472     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19<56:BMDCVO>2.0.CO;2     Document Type: Article

References (39)

1. Goldschmidt MH. Pigmented lesions of the skin. Clin Dermatol 1994;12:507-514.
2. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol 2002;39:651-678.
3. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol 1979;16:32-40.
4. Ramos-Vara JA, Beissenherz ME, Miller MA, et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol 2000;37:597-608.
5. Koenig A, Bianco SR, Fosmire S, et al. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 2002;39:458-472.
6. Kirkin AF, Dzhandzhugazyan K, Zeuthen J. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet 1998;15:19-32.
7. Bramson JL, Wan YH. The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin Biol Ther 2002;2:75-85.
8. Blackwood L, Dobson JM. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc 1996;209:98-102.
9. Modiano JF, Ritt MG, Wojcieszyn J. The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy. J Vet Intern Med 1999;13:163-174.
10. Bateman KE, Catton PA, Pennock PW, Kruth SA. 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med 1994;8:267-272.
11. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:4249-4258.
12. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clin Cancer Res 2003;9:1284-1290.
13. Soergel SA, MacEwen EG, Vail DM, et al. The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma. J Immunother 1999;22:443-453.
14. Bianco SR, Sun J, Fosmire SP, et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther 2003;10:726-736.
15. Haigh PI, Difronzo LA, Gammon G, Morton DL. Vaccine therapy for patients with melanoma. Oncology (Huntingt) 1999;13:1561-1574.
16. Wang RF. Tumor antigens discovery: Perspectives for cancer therapy. Mol Med 1997;3:716-731.
17. Engelhard VH, Bullock TN, Colella TA, Mullins DW. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Cancer J 2000;6 Suppl 3:S272-S280.
18. Lane C, Leitch J, Tan X, et al. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 2004;64:1509-1514.
19. Hawkins WG, Gold JS, Blachere NE, et al. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res 2002;102:137-143.
20. Gold JS, Ferrone CR, Guevara-Patino JA, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170:5188-5194.
21. Nawrath M, Pavlovic J, Moelling K. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. J Mol Med 2001;79:133-142.
22. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000;11:797-806.
23. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001;7:761-765.
24. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-2473.
25. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene 2000;19:6673-6679.
26. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003;30:23-29.
27. Nestle FO. Vaccines and melanoma. Clin Exp Dermatol 2002; 27:597-601.
28. Wan Y, Emtage P, Zhu Q, et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999;198:131-138.
29. Wan Y, Bramson J, Pilon A, et al. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: Implications for cancer vaccines. Cancer Res 2000;60:3247-3253.
30. Sulaimon S, Kitchell B, Ehrhart E. Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma. J Comp Pathol 2002;127:162-168.
31. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-896.
32. Kaplan JM, Yu Q, Piraino ST, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999;163:699-707.
33. Hagglund HG, McSweeney PA, Mathioudakis G, et al. Ex vivo expansion of canine dendritic cells from CD34+ bone marrow progenitor cells. Transplantation 2000;70:1437-1442.
34. Catchpole B, Stell AJ, Dobson JM. Generation of blood-derived dendritic cells in dogs with oral malignant melanoma. J Comp Pathol 2002;126:238-241.
35. Coulon V, Ravaud A, Gaston R, et al. In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates. Int J Cancer 2000;88:783-790.
36. Yang S, Vervaert CE, Burch J Jr, et al. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Int J Cancer 1999;83:532-540.
37. Dow SW, Elmslie RE, Willson AP, et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998;101:2406-2414.
38. Catchpole B, Gould SM, Kellett-Gregory LM, Dobson JM. Development of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogs. Am J Vet Res 2003;64:544-549.
39. Koenig A, Wojcieszyn J, Weeks BR, Modiano JF. Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma. Vet Pathol 2001;38:427-435.